The Video Journal of Hematology and Hematological Oncology / X
Jul 19, 2025, 19:00
Steven Treon on Promising Advances: 3 Novel Therapies Transforming Waldenström’s Macroglobulinemia
The Video Journal of Hematology and Hematological Oncology shared a post on X:
”What are some of the most exciting developments in the field of Waldenström’s macroglobulinemia? We caught up with Steven Treon of Dana-Farber Cancer Institute at 18 ICML to find out!”
Watch the interview here.
Dr. Steven Treon highlights promising advances in Waldenström’s macroglobulinemia, focusing on novel therapies like BTK degraders, that demonstrate strong efficacy, even in resistant cases, as well as non-covalent BTK inhibitors and BCL2 inhibitors.
His insights were shared at the 18th International Conference on Malignant Lymphoma in Lugano.
Latest scientific advancements in hematology highlighted in Hemostasis Today.
-
Oct 16, 2026, 13:59Aya Akmal Amin: Antiphospholipid Syndrome Management and Risk Stratification
-
Oct 16, 2026, 13:10Emanuel Sueldo: CAHT 2026 Celebrates Scientific Progress and Team Achievements
-
Oct 16, 2026, 13:05Maha Othman: Queen’s Health Sciences Advances CAT Risk Models and Pediatric ISTH-BAT Cut-Offs
-
Oct 16, 2026, 13:03Thrombosis Awareness Must Lead to Timely Action – Roche
-
Oct 16, 2026, 12:49Wolfgang Miesbach: 5-Year CBDR Data Confirms Emicizumab Safety and Efficacy in Hemophilia A
-
Oct 16, 2026, 12:40Edward Lee Carter: How Factor XI Inhibition Could Transform Anticoagulation Therapy
-
Oct 16, 2026, 12:40Marc Carrier: Looking Ahead to ISTH 2027 in Vancouver
-
Oct 16, 2026, 12:30Bob Lempke: How One Blood Donation Can Save Up to Three Lives
-
Oct 16, 2026, 12:30Why VWF Therapies Belong on the EU Critical Medicines List – EHC